Summary: Week of 2/22/25
Biobot’s national wastewater network shows that COVID-19, influenza A, and RSV are decreasing, while influenza B continues to increase in week 8 (through February 22, 2025). National hospitalizations for influenza remain the highest compared to the other respiratory viruses but are also decreasing, currently at 10.2 per 100,000 people in week 7 (through February 15, 2025). National hospitalizations for COVID-19 and RSV decreased in week 7, currently both at 2.5 per 100,000 people.
The Bottom Line: Despite decreases, flu activity remains high right now — we can expect several more weeks of elevated transmission. It’s good to remember these recommendations to stay healthy: stay current with vaccinations, consider wearing a mask in crowded areas, and if you feel unwell, minimize contact with others.
National Outlook
COVID-19
National SARS-CoV-2 concentrations are decreasing.
Influenza
National influenza A concentrations are decreasing while influenza B concentrations are increasing.
RSV
National RSV concentrations are decreasing.
Regional
The South
COVID-19: SARS-CoV-2 concentrations are decreasing in the South.
Influenza: Influenza A concentrations are decreasing in the South, while influenza B is increasing.
RSV: RSV concentrations are decreasing in the South.
The Midwest
COVID-19: SARS-CoV-2 concentrations are decreasing in the Midwest.
Influenza: Influenza A concentrations are holding steady in the Midwest, while influenza B is increasing.
RSV: RSV concentrations are fluctuating in the Midwest.
The Northeast
COVID-19: SARS-CoV-2 concentrations are decreasing in the Northeast.
Influenza: Influenza A concentrations are decreasing in the Northeast, while influenza B is increasing.
RSV: RSV concentrations are decreasing in the Northeast.
The West
COVID-19: SARS-CoV-2 concentrations are decreasing in the West.
Influenza: Influenza A concentrations are decreasing in the West, while influenza B is increasing.
RSV: RSV concentrations are holding steady in the West.
Footnotes:
We continue to monitor the evolving H5N1 influenza virus situation, and can now test samples specifically for H5 (including H5N1) — please reach out to hello@biobot.io if interested. A quick reminder that Biobot’s influenza A assay described in this report includes the H5N1 influenza subtype, which is an influenza A virus, but does not distinguish between the different subtypes of influenza A (e.g. H5N1 vs H1N1). We will share any important updates as we have them via Twitter and Bluesky, and in the risk reports.
Wastewater data from Biobot Analytics for RSV, influenza, and SARS-CoV-2 are through February 22, 2025 (MMWR week 8). Clinical data for RSV, influenza, and COVID-19 are from the Centers for Disease Control and Prevention. Updates to clinical data are through February 15, 2024 (MMWR week 7).